OPA 6566

Drug Profile

OPA 6566

Alternative Names: OPA-6566

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Adenosine A2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 14 Jun 2016 Otsuka Pharmaceutical terminates its collaboration agreement with Acucela for OPA 6566 in USA
  • 11 Mar 2016 Otsuka has patent protection for OPA 6566 in USA (Acucela, Form 10-K, March 2016)
  • 21 Sep 2015 OPA 6566 is in phase-I/II development for Glaucoma and Ocular hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top